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Abstract
Objective—To examine associations of perceived stress with cognitive symptoms among adults 
with systemic lupus erythematosus (SLE).
Methods—Among 777 adult (>18 years) SLE patients, we examined the association of Perceived 
Stress Scale (PSS) scores with two self-reported cognitive symptoms: forgetfulness [severe/
moderate vs. mild/none; from the Systemic Lupus Activity Questionnaire] and difficulty 
concentrating (all/most vs. some/little/none of the time; from the Lupus Impact Tracker). We used 
multivariable logistic regression to estimate the odds ratios (ORs) per minimal important 
difference (MID=0.5*SD) of PSS score and cognitive symptoms.
Results—Forgetfulness and difficulty concentrating were reported by 41.7% and 29.5%, 
respectively. Women and those with less education and high disease activity had higher PSS scores 
and were more likely to report cognitive symptoms than their counterparts. With adjustment for 
age, race, sex, education, and disease activity, each MID increase in PSS score was associated with 
higher prevalence of forgetfulness (OR=1.43, 95% CI 1.29–1.47) and difficulty concentrating 
(OR=2.19, 95% CI 1.90–2.52). No substantial differences in this association by age, race, sex, or 
disease activity were noted.
Conclusions—SLE patients, particularly those with high disease activity, report a high burden 
of cognitive symptoms, for which stress may be a modifiable risk factor.
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Signs and symptoms of cognitive dysfunction are common in systemic lupus erythematosus 
(SLE) patients, with about one-quarter to one-half of patients experiencing some level of 
cognitive impairment (1–3). Multiple biologic factors, such as immunologic mechanisms 
and neuropsychiatric involvement in SLE, to explain the so-called “lupus brain fog” have 
been explored (4–6). However, psychosocial factors such as stress may also act as 
contributors to this impairment. High levels of perceived stress have been shown to be 
strongly associated with cognitive impairment in older adults generally (7, 8) and in other 
chronic, inflammatory diseases as diverse as HIV (9), breast cancer (10), and multiple 
sclerosis (11). This association may also hold in SLE patients, in whom stress is commonly 
reported, with nearly half reporting major life stress in the past 6 months (12). Stress 
represents one of many psychosocial factors that may interact with each other and with 
disease-related factors to produce symptoms of cognitive impairment in SLE (13), but stress 
may also exert effects on cognitive function that are independent of the effects of disease-
specific SLE activity.
Thus, stress represents a potentially modifiable risk factor for poor cognitive function in 
SLE patients that would not be addressed by clinical approaches that primarily address the 
contribution of disease activity to cognitive dysfunction in SLE (14, 15). However, few 
studies have explicitly examined the independent association of stress with cognitive 
dysfunction in SLE. While a recent Spanish study found that higher stress was associated 
with greater cognitive dysfunction in a small sample of SLE patients (16), better 
understanding of this association in a larger, representative population of SLE patients—
particularly, a population that includes African-American patients, who may experience 
stress and its effects on health differently (17)—will inform clinical care for the broader SLE 
population. Leveraging cross-sectional data from the ongoing U.S. cohort, Georgians 
Organized Against Lupus (GOAL), which enrolled large numbers of adult SLE patients who 
are African-American, we examined whether perceived stress was independently associated 
with reported cognitive symptoms, including forgetfulness and difficulty concentrating, 
among SLE patients and whether these associations were independent of SLE-specific 
disease activity. We also examined whether the association between stress and cognitive 
symptoms differed among subpopulations of interest.
Methods
Study Design and Population
We used a cross-sectional design to describe the association of perceived stress with 
cognitive symptoms in baseline data from the ongoing GOAL cohort study. Details of 
GOAL recruitment and data collection have been published previously (18). Briefly, GOAL 
study participants were recruited primarily from the existing Georgia Lupus Registry, a 
population-based registry funded by the Centers for Disease Control and Prevention for the 
purpose of more accurately estimating the incidence and prevalence of SLE in metropolitan 
Atlanta (19). The population-based cohort was further enriched with additional patients 
receiving SLE treatment at Emory University, at Grady Memorial Hospital (the only safety 
net hospital in Atlanta), or from community rheumatologists in metropolitan Atlanta, who 
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were recruited by mail, by telephone, and in person. Eligible participants were adult patients 
(aged ≥18 years) with a documented diagnosis of SLE [≥4 revised American College of 
Rheumatology (ACR) criteria (20), or 3 ACR criteria plus a diagnosis of SLE by the 
patient’s treating board-certified rheumatologist].
Baseline (8/2011–7/2012) data were available for 800 patients. For analyses, patients were 
excluded if they were missing data on perceived stress (n=1) or cognitive symptoms (n=7). 
Because of small sample sizes, we were unable to stratify by race other than African-
American or white; thus, patients were further excluded if their race was not African-
American or white (n=15), leaving 777 SLE patients in the analytic sample. The Emory 
University Institutional Review Board, Grady Health System Research Oversight 
Committee, and Georgia Department of Public Health Institutional Review Board approved 
the GOAL study protocol. All GOAL participants provided informed consent.
Study Variables
Perceived stress—Perceived stress was estimated using the 10-item Perceived Stress 
Scale (PSS) score (21), which measures the degree to which the subject found life situations 
stressful during the prior month. PSS scores range from 0 to 40, with higher scores 
indicating greater perceived stress; mean scores in a probability-based U.S. sample were 
12.1 and 13.7 in males and females, respectively (22).
Cognitive symptoms—Self-reported cognitive symptoms were taken from items 
included in instruments measuring disease activity and lupus impact at baseline.
Forgetfulness: Forgetfulness was assessed by the item “In the past 3 months, how bad has 
your forgetfulness been?” (with possible responses of “no problem,” “mild,” “moderate,” or 
“severe”) from the Systemic Lupus Activity Questionnaire (SLAQ) (23). We dichotomized 
forgetfulness as severe/moderate vs. mild/none.
Difficulty concentrating: Difficulty concentrating was assessed by the item “During the 
past 4 weeks, I experienced difficulty concentrating” (with possible responses of “none of 
the time,” “a little of the time,” “some of the time,” “most of the time,” and “all of the 
time”), from the Lupus Impact Tracker (LIT) (24). We dichotomized difficulty concentrating 
as all/most vs. some/little/none of the time.
Other variables—Sociodemographics, including age, sex, race, years of education 
completed, employment status, income, and marital status, were self-reported at baseline. 
Age was grouped into categories of 20–39, 40–59, and >60 years for stratified analyses. 
Current disease activity was assessed via SLAQ (23) (range, 0–44, with higher scores 
indicating greater SLE-related disease activity). Strata for high vs. low disease activity were 
defined by the median SLAQ score, excluding the forgetfulness item. SLE duration was 
calculated as the number of years between age at SLE onset and age at survey. SLE-related 
organ damage was assessed via the self-administered Brief Index of Lupus Damage (BILD; 
range, 0–30, with higher scores indicating greater levels of damage) (25, 26).
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Sociodemographic and clinical patient characteristics were summarized overall, and PSS 
scores and cognitive symptoms were summarized overall and by select characteristics. Odds 
ratios (ORs) and 95% confidence intervals (CIs) for the associations between dichotomized 
cognitive symptoms and PSS score were estimated with multivariable logistic regression 
models. PSS score was transformed such that resulting ORs representing relative change in 
odds per minimal important difference (MID), estimated as 0.5*SD (27), since, to our 
knowledge, there is no published minimal clinically important difference for this non-
clinical assessment, particularly in SLE (25). Adjustment for a priori confounders age, sex, 
race, education, and disease activity was performed. In sensitivity analyses, we examined the 
effects of additional adjustment for employment, income, marital status, and current steroid 
use. Stata v. 14 (StataCorp, College Station, TX) was used for all analyses and the threshold 
for statistical significance was set at α =0.05.
Results
Patient Characteristics
The mean age of patients at baseline was 46.4 years; 6.4% were male and 80.3% were 
African-American (Table 1). Most had at least 12 years of education, but only 35% of 
patients were employed (with 67% of those who were not working being disabled) and 
nearly half earned <$20,000 annually (Table 1). The mean duration of SLE at baseline was 
14 years, and the median disease activity (SLAQ) score, excluding the forgetfulness 
symptom, was 15 (Table 1).
Perceived Stress
The overall mean PSS score was 18, with the entire range of possible scores (0–40) 
represented in the cohort (Figure 1); 16.1% and 6.1% reported scores <10 and >30, 
respectively. PSS scores were, on average, higher in younger patients, patients with fewer 
years of education and with lower income, and patients who were not married (Table 2). 
African-American and female participants reported higher stress scores than white and male 
participants, respectively, but no statistically significant differences by race or sex were 
noted. On average, PSS scores were 1.5-fold higher in participants reporting higher vs. lower 
disease activity (mean scores of 22 vs. 14; Table 1).
Association of Perceived Stress with Reported Cognitive Symptoms in a Cohort of SLE 
Patients
Forgetfulness—Overall, 42% of patients reported severe or moderate forgetfulness (Table 
2); 34% of these patients (14% of all patients) reported severe forgetfulness. Female patients 
were nearly twice as likely as male patients to report severe or moderate forgetfulness (43% 
vs. 22%, P=0.003), but no differences by age or race were seen (Table 2). Patients with the 
most years of education and highest income reported were less likely, whereas patients who 
were not working due to disability were more likely, to report forgetfulness, relative to other 
patients (Table 2). Forgetfulness was reported nearly 3-fold more often with high vs. low 
disease activity (59% vs. 22%, P<0.001; Table 2).
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Overall, each MID increase in PSS score was associated with 60% higher reported 
forgetfulness (OR=1.60, 95% CI 1.46–1.74); adjustment for sociodemographics did not 
change the association (Figure 2). Further adjustment for disease activity resulted in only a 
slightly attenuated association (OR=1.43, 95% CI 1.29–1.57), despite high vs. low disease 
activity being associated with nearly 3-fold greater prevalence of reported forgetfulness in 
the same model (OR=2.92, 95% CI 2.05–4.15). Additional adjustment for employment, 
income, marital status, and steroid use did not change the results substantially (data not 
shown). Finally, stratified analyses showed no statistically significantly differences in 
association of PSS score with forgetfulness by age, sex, race, or disease activity (Table 3), 
although the magnitude of the associations were stronger in males vs. females and in those 
with low vs. high disease activity.
Difficulty concentrating—Nearly one-third (30%) of patients reported difficulty 
concentrating all or most of the time (Table 2); 35% of these patients (10% of all patients) 
reported difficulty concentrating all of the time. Female patients were 1.5-fold more likely 
than male patients to report difficulty concentrating all or most of the time (30% vs. 20%, 
P<0.001), but there were no differences by age or race (Table 2). As with forgetfulness, 
patients with the most years of education and highest income reported were less likely, and 
patients who were not working due to disability were more likely, to report difficulty 
concentrating, relative to other patients (Table 2). Those who were separated, divorced, or 
widowed were also more likely than married or never-married patients to report difficulty 
concentrating. Difficulty concentrating was reported nearly 4-fold more often with high vs. 
low disease activity (45% vs. 12%, P<0.001; Table 2).
Overall, each MID increase in PSS score was associated with 2.3-fold higher prevalence of 
reported difficulty concentrating (OR=2.31, 95% CI 1.90–2.52); adjustment for 
sociodemographics did not change the association (Figure 2). Further adjustment for disease 
activity resulted in only a slightly attenuated association (OR=2.19, 95% CI 1.90–2.52), 
although high vs. low disease activity was associated with 2.7-fold greater prevalence of 
difficulty concentrating (OR=2.70, 95% CI 1.75–4.19). Additional adjustment for 
employment, income, marital status, and steroid use did not change the results substantially 
(data not shown). Finally, there were no differences in association of PSS score with 
difficulty concentrating by age, sex, race, or disease activity (Table 3).
Discussion
In this large, predominantly African-American U.S. cohort of SLE patients, we found 
perceived stress levels are high, with only about one-quarter of the population having scores 
below the comparable mean score in the general U.S. population (22). Furthermore, >40% 
of these patients reported moderate-to-severe problems with forgetfulness, and nearly 30% 
reported difficulty concentrating all or most of the time. Both stress scores and prevalence of 
these cognitive symptoms were positively associated with younger age, less education, lower 
income, and high disease activity. However, even with adjustment for these and other 
potentially confounding factors, higher stress scores remained strongly associated with 
higher prevalence of these cognitive symptoms.
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These results suggest that, in addition to managing disease activity, an approach that also 
includes stress reduction may be necessary to manage cognitive symptoms in patients with 
SLE. For example, self-management programs may work to decrease stress among SLE 
patients (29). Cognitive behavioral therapy has also been shown to decrease perceived stress 
in the SLE population (30). In another randomized study of SLE patients (32), a stress 
reduction program consisting of biofeedback-assisted cognitive behavioral therapy reduced 
pain perception and improved psychological and physical functioning. Although not 
currently available on a routine basis, these types of interventions could have multiple 
patient-centered benefits, in addition to the potential for decreasing perceived stress and 
improving cognitive symptoms.
One limitation of our study is the lack of measured cognitive performance. Peralta-Ramirez 
et al. (16) looked at the association between stress and measured cognitive domains (e.g., 
visual memory, fluency attention) in 21 Spanish patients and found a similar association 
between higher stress and poorer cognitive function. However, while the self-reported 
cognitive symptoms that were used as outcomes in this study may be only perceived and 
may not reflect underlying changes in cognitive processes, these symptoms remain 
associated with concomitant stress. Furthermore, SLE patients see their perceived cognitive 
impact of lupus (including impaired ability to think clearly, concentration problems, and 
memory problems) as a primary component of their overall health-related quality of life, 
which further affects other important aspects of their quality of life, particularly employment 
and social functioning (32).
We also have the advantage of being able to examine many more patients who are more 
representative of the diverse U.S. population with SLE than in previous studies such as 
Peralta-Ramirez et al. (16). We were able to leverage this population to examine stress, 
cognitive symptoms, and their association across several subgroups of interest. Interestingly, 
older age (≥60 years) was not associated with higher prevalence of cognitive symptoms, as 
might be expected for indicators of cognitive dysfunction; in fact, the younger patients 
reported higher prevalence of these symptoms, as well as higher stress levels. While fewer 
reported cognitive symptoms among older patients may reflect changing expectations and 
better coping strategies with increasing age, it is still important to note that younger patients, 
who are more likely to be in school or to be employed or seeking employment, are reporting 
high prevalence of these potentially devastating cognitive symptoms. Male SLE patients 
were far less likely than female SLE patients to report cognitive symptoms, but our results 
suggest that the effect of stress on cognitive symptoms may be stronger in male vs. female 
SLE patients. However, the latter results did not reach statistical significance, which may be 
due to lack of power, given the small sample of male SLE patients. Notably, there were no 
differences by race in reported stress, cognitive symptoms, or their association, despite 
generally poorer SLE outcomes in African-American vs. white SLE patients. Other 
psychosocial factors, including fewer years of education, disabled employment status, lower 
income, and unmarried status, were all associated with higher reported stress and higher 
prevalence of cognitive symptoms. Disease activity was a stronger predictor of stress and 
cognitive symptoms than any individual psychosocial factor. However, disease activity and 
psychosocial factors combined still did not explain the strong association between higher 
stress and higher prevalence of reported cognitive symptoms. Even additional adjustment for 
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other factors such as use of steroids, which have been shown to be associated with reduced 
cognitive function (33), did not change the association.
There are several important limitations to this work not discussed above. In this cross-
sectional study, causal inference is limited. Further, the cross-sectional nature of the study 
does not allow for longitudinal examinations of cognitive symptoms or chronic stress (e.g., 
monthly stress inventories implemented by Peralta-Ramirez et al. (16)) or for the ability to 
distinguish effects of perceived stress on subsequent disease activity vs. effects of disease 
activity on subsequent perceived stress. However, regardless of the direction of this 
association, our results still suggest that a clinical approach that addresses both disease 
activity and stress reduction is likely to be more effective than an approach that primarily 
addresses disease activity. Another important limitation is that we did not have a comparison 
group; thus, we cannot know whether the prevalence of cognitive symptoms is higher than 
that in a similar or even matched population. Despite this, knowledge of the association 
between stress and cognitive symptoms among SLE patients still informs their clinical care. 
Finally, as in any observational study, there is the possibility of residual confounding. For 
example, unmeasured factors such as social support and coping strategies (12, 34, 35) might 
at least partially explain our results. Our study also had important strengths, including 
relative large sample sizes allowing subgroup analyses, a population-based sample of SLE 
patients, and adequate representation of African-American SLE patients.
SLE patients of all ages may be highly susceptible to cognitive symptoms, which are often 
considered to be geriatric issues in the general population. Further, these cognitive 
symptoms are strongly associated with higher perceived stress, regardless of disease activity 
or other patient characteristics. Stress is a modifiable risk factor that could be incorporated 
into a more patient-centered approach to cognitive symptoms in SLE.
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Distribution of perceived stress scores among a cohort of systemic lupus erythematosus 
patients, August 2011–July 2012. Solid line, mean/median (=18); dashed lines, interquartile 
range (=13–23). IQR, interquartile range; PSS, Perceived Stress Scale.
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Association of cognitive symptoms with perceived stress among a cohort of systemic lupus 
erythematosus patients, August 2011–July 2012. Triangles, forgetfulness (severe/moderate 
vs. mild/none); squares, difficulty concentrating (all/most vs. some/little/none of the time). 
MID, minimal important difference (=4.03 points); PSS, perceived stress score. 
Sociodemographics include age group, sex, race, and education; disease activity includes the 
Systemic Lupus Activity Questionnaire score (excluding the forgetfulness item).
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Table 1
Baseline characteristics of a cohort of systemic lupus erythematosus patients, August 2011–July 2012
Characteristic N Overall
Sociodemographic
Mean (SD) age at survey 777 46.4 (13.3)
Male, n (%) 777 50 (6.4)
African-American race, n (%) 777 624 (80.3)
Years of education, n (%) 774
 <12 71 (9.2)
 12–15 456 (58.9)
 16+ 247 (31.9)
Employment, n (%) 776
 Employed 272 (35.1)
 Not employed* 166 (21.4)
 Disabled 338 (43.6)
Income, n (%) 754
 <$20,000 368 (48.8)
 $20–49,999 200 (26.5)
 ≥$50,000 186 (24.7)
Marital status, n (%) 777
 Never married 276 (35.5)
 Married 271 (34.9)
 Separated/divorced/widowed 230 (29.6)
Clinical
Mean (SD) duration of SLE, years 775 13.6 (9.3)
Mean (SD) BMI 774 29.0 (7.6)
On steroids, n (%) 746 425 (57.0%)
Median (IQR) SLAQ score** 777 15 (9–22)
Median (IQR) BILD score 777 2 (0–3)
SD, standard deviation; IQR, interquartile range; BMI, body mass index; BILD, Brief Index of Lupus Damage; SLAQ, Systemic Lupus Activity 
Questionnaire.
*
Includes retired, student, and homemaker.
**
Excluding the forgetfulness item.
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Table 2
Perceived stress and cognitive symptoms among a cohort of systemic lupus erythematosus patients, August 
2011–July 2012, overall and by patient characteristics
Patient characteristic N PSS score,* Mean (SD)
Reported cognitive symptom,** n (%)
Forgetfulness Difficulty concentrating
Overall 777 18.0 (8.1) 324 (41.7%) 229 (29.5%)
Age
 18–39 252 19.2 (8.1) 110 (43.7%) 67 (26.6%)
 40–59 398 17.9 (8.0) 169 (42.5%) 127 (31.9%)
 60+ 127 15.8 (7.8) 45 (35.4%) 35 (27.6%)
P*** <0.001 0.28 0.31
Race
 African-American 624 18.2 (8.1) 263 (42.2%) 184 (29.5%)
 White 153 17.3 (8.0) 61 (39.9%) 45 (29.4%)
P*** 0.23 0.61 >0.9
Sex
 Male 50 16.9 (7.6) 11 (22.0%) 10 (20.0%)
 Female 727 18.1 (8.1) 313 (43.1%) 219 (30.1%)
P*** 0.33 0.003 <0.001
Years of education
 <12 71 19.8 (6.7) 33 (46.5%) 24 (33.8%)
 12–15 456 18.8 (7.9) 203 (44.5%) 150 (32.9%)
 16+ 247 16.1 (8.4) 87 (35.2%) 55 (22.3%)
P*** <0.001 0.04 0.009
Employment
 Employed 272 16.0 (8.3) 88 (32.4%) 49 (18.0%)
 Not employed 166 16.7 (7.8) 61 (36.8%) 42 (25.3%)
 Disabled 338 20.3 (7.4) 175 (51.8%) 138 (40.8%)
P*** <0.001 <0.001 <0.001
Income
 <$20,000 368 19.8 (7.4) 174 (47.3%) 131 (35.6%)
 $20–49,999 200 17.8 (8.0) 90 (45.0%) 59 (29.5%)
 ≥$50,000 186 15.0 (6.8) 53 (28.5%) 36 (19.4%)
P*** <0.001 <0.001 <0.001
Marital status
 Never married 176 18.5 (7.9) 117 (42.4%) 78 (28.3%)
 Married 271 16.8 (8.2) 103 (38.0%) 69 (25.5%)
 Separated/divorced/widowed 230 18.9 (7.9) 104 (45.2%) 82 (35.7%)
P*** 0.006 0.25 0.04
Disease activity****
 High 412 21.5 (7.0) 242 (58.7%) 187 (45.4%)
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Patient characteristic N PSS score,* Mean (SD)
Reported cognitive symptom,** n (%)
Forgetfulness Difficulty concentrating
 Low 365 14.0 (7.3) 82 (22.5%) 42 (11.5%)
P*** <0.001 <0.001 <0.001
*
PSS, Perceived Stress Scale. Score range, 0–40.
**
Forgetfulness, severe/moderate vs. mild/none; difficulty concentrating, all/most vs. some/little/none of the time.
***
By t test, ANOVA, or chi-square test, as appropriate.
****
Systemic Lupus Activity Questionnaire score (excluding forgetfulness item) ≥15 (high) or <15 (low).
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Table 3
Association of cognitive symptoms with perceived stress among a cohort of systemic lupus erythematosus 
patients, August 2011–July 2012, by patient characteristics
Patient characteristic
Odds ratio (95% CI),per minimal important difference in PSS score (=4.03 points)
Unadjusted Adjusted* for sociodemographics Adjusted* for sociodemographics + disease activity
Forgetfulness (severe/moderate vs. mild/none)
Age
 <40 1.74 (1.47–2.07) 1.77 (1.47–2.12) 1.59 (1.32–1.93)
 40–59 1.53 (1.35–1.72) 1.55 (1.36–1.75) 1.38 (1.20–1.58)
 60+ 1.58 (1.25–1.99) 1.59 (1.25–2.02) 1.47 (1.13–1.91)
P** 0.37 0.40 0.33
Sex
 Male 2.99 (1.43–6.22) 8.58 (1.74–42.3) 9.37 (1.41–62.4)
 Female 1.57 (1.43–1.72) 1.56 (1.42–1.72) 1.40 (1.27–1.55)
P** 0.09 0.09 0.14
Race
 African-American 1.57 (1.29–1.92) 1.67 (1.33–2.09) 1.43 (1.28–1.60)
 White 1.60 (1.45–1.77) 1.59 (1.43–1.76) 1.49 (1.17–1.89)
P** 0.87 0.76 0.75
Disease activity***
 High 1.33 (1.18–1.51) 1.33 (1.17–1.50) 1.33 (1.17–1.50)
 Low 1.59 (1.35–1.87) 1.61 (1.36–1.90) 1.61 (1.36–1.90)
P** 0.09 0.10 0.10
Difficulty concentrating (all/most vs. some/little/none of the time)
Age
 <40 2.66 (2.02–3.51) 2.62 (1.98–3.46) 2.40 (1.79–3.21)
 40–59 2.18 (1.83–2.60) 2.18 (1.83–2.60) 1.99 (1.66–2.38)
 60+ 2.93 (1.97–4.37) 3.14 (2.04–4.84) 3.23 (2.03–5.13)
P** >0.9 0.88 >0.9
Sex
 Male 2.44 (1.27–4.70) 2.61 (1.19–5.72) 1.69 (0.73–3.93)
 Female 2.30 (2.01–2.63) 2.40 (2.08–2.77) 2.22 (1.91–2.57)
P** 0.86 0.88 0.87
Race
 African-American 2.36 (2.03–2.75) 2.45 (2.09–2.87) 2.26 (1.92–2.66)
 White 2.15 (1.63–2.83) 2.22 (1.65–2.99) 1.97 (1.45–2.70)
P** 0.56 0.53 0.52
Disease activity***
 High 2.12 (1.79–2.50) 2.16 (1.82–2.56) 2.16 (1.82–2.56)
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Patient characteristic
Odds ratio (95% CI),per minimal important difference in PSS score (=4.03 points)
Unadjusted Adjusted* for sociodemographics Adjusted* for sociodemographics + disease activity
 Low 2.09 (1.64–2.65) 2.33 (1.77–3.07) 2.33 (1.77–3.07)
P** 0.24 >0.9 >0.9
PSS, Perceived Stress Scale.
*
Adjusted for: sociodemographics (age group, sex, race, and education) and disease activity (Systemic Lupus Activity Questionnaire score, 
excluding the forgetfulness item).
**
P for interaction of characteristic with perceived stress score.
***
Systemic Lupus Activity Questionnaire score (excluding forgetfulness item) ≥15 (high) or <15 (low).
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